Published in Blood Weekly, June 8th, 1998
V.I. Technologies, Inc. (VITEX) received U.S. Food and Drug Administration (FDA) licensure approval for PLAS+SD which it manufactures for the Red Cross. PLAS+SD is the first FDA-approved product to virtually eliminate specific viruses in the plasma component of the blood. The American Red Cross expected to begin product distribution during the week of May 18, 1998.
Chris Lamb, American Red Cross, said, "The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.